Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kailera TherapeuticsKLRA +2.24%11 Current Ratio is 12.01 as of Dec. 2025, which is 36% below its 10-year median of 18.86. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Kailera Therapeutics ranks better than 82.14% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Kailera Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 12.01.
Kailera Therapeutics has a current ratio of 12.01. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Kailera Therapeutics's Current Ratio or its related term are showing as below:
KLRA'
s Current Ratio Range Over the Past 10 Years
Min: 12.01 Med: 18.86 Max: 25.7
Current: 12.01
During the past 2 years, Kailera Therapeutics's highest Current Ratio was 25.70. The lowest was 12.01. And the median was 18.86.
KLRA's Current Ratio is ranked better than 82.14% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs KLRA: 12.01
Kailera Therapeutics (NAS:KLRA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Kailera Therapeutics Current Ratio Related Terms
Kailera Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Kailera Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kailera Therapeutics Current Ratio Chart
Kailera Therapeutics Annual Data
Trend
Dec24
Dec25
Current Ratio
25.70
12.01
Kailera Therapeutics Semi-Annual Data
Dec24
Dec25
Current Ratio
25.70
12.01
KLRA vs VCEL, NUVB, IOVA: Current Ratio Comparison
For the Biotechnology subindustry, Kailera Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kailera Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Kailera Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kailera Therapeutics (KLRA) has a Current Ratio of 12.01 as of Dec. 2025. This is 36% below median its historical median of 18.86. Over the past decade, Kailera Therapeutics' Current Ratio has ranged from 12.01 to 25.70. According to the industry distribution chart, Kailera Therapeutics ranks #252 out of 1411 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Kailera Therapeutics' Current Ratio too high?
Kailera Therapeutics' current Current Ratio of 12.01 is 36% below median its 10-year median of 18.86. Over the past 10 years, this metric has ranged from a low of 12.01 to a high of 25.70. The Biotechnology industry median Current Ratio is 3.85. Kailera Therapeutics' value of 12.01 is 211.9% above this industry median. Based on the distribution chart, Kailera Therapeutics ranks #252 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Current Ratio compare to VCEL and NUVB?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #252 out of 1411 companies for Current Ratio. This places Kailera Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Kailera Therapeutics' value of 12.01 is 211.9% above this benchmark. Historically, Kailera Therapeutics' own Current Ratio has ranged from 12.01 to 25.70 over the past decade. While the company's 10-year median is 18.86 vs. the industry median of 3.85, Kailera Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kailera Therapeutics's current Current Ratio of 12.01 is 211.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kailera Therapeutics's current Current Ratio is 12.01, which is 36% below median its own 10-year median of 18.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Current Ratio of 12.01. The current Current Ratio is 12.01, which is 36% below median its 10-year median of 18.86 and 211.9% above the Biotechnology industry median of 3.85. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Current Ratio is 12.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score
Get the complete analysis for KLRA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRA has been successfully added to your 
